Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Jefferam1on Dec 02, 2016 9:07am
154 Views
Post# 25545276

RE:RE:RE:RE:Antibe Therapeutics Reports Q2 2017 Interim Financial and Op

RE:RE:RE:RE:Antibe Therapeutics Reports Q2 2017 Interim Financial and OpYeah I hear you, I'd say I have about 90% of my full position, I'm still prepared to buy a bit more if they drop to 0.12 or so. Great if they do so I can buy some super cheap shares, but no worries if they don't as that means they are going up.
I have very high hopes for the next 12-18 months.
I'm just a little more concerned that I might be a little unwisely too overweighed in ATE.
Perhaps I'm approaching this all wrong, but I'm banking on ATE to be my retirement strategy.
I realize they have lots of risk on the financial side, however seeing their results, I can't imagine a situation where they won't be able to raise the required funds. Once that's complete, this stock has the making for 100x multiplier. A few more positive clinical trials this becomes a $1.00 stock on it's way to 5$,10$. Just a matter of time.



Bullboard Posts
Dealroom for high-potential pre-IPO opportunities